Aryl sulfonamides as BLT1 antagonists
US12264139B2 · kind B2 · utility
0Cited by
10References
18Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jun 10, 2021 |
| Grant date | Apr 1, 2025 |
| Priority date | — |
| Expiry date | Nov 13, 2042 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D417/06
- WIPO fieldOrganic fine chemistry
- WIPO sectorChemistry
Abstract
Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are antagonists of leukotriene B4 receptor 1 (BLT1) and may be useful in the treatment, prevention and suppression of diseases mediated by the leukotriene B4 receptor 1 (BLT1). The compounds of the present invention may be useful in the treatment of Type 2 diabetes mellitus, insulin resistance, hyperglycemia, dyslipidemia, lipid disorders, obesity, hypertension, Nonalcoholic fatty liver disease/nonalcoholic steatohepatitis, metabolic syndrome, atherosclerosis, and cancer.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.